Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $2.9 million.

  • Iovance Biotherapeutics' Depreciation & Amortization (CF) fell 2.07% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 9.82%. This contributed to the annual value of $12.0 million for FY2024, which is 3.45% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Depreciation & Amortization (CF) of $2.9 million as of Q3 2025, which was down 13.59% from $3.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Depreciation & Amortization (CF) high stood at $4.0 million for Q4 2024, and its period low was $2.8 million during Q1 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Depreciation & Amortization (CF) value was $3.0 million (recorded in 2023), while the average stood at $3.1 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Depreciation & Amortization (CF) spiked by 34.85% in 2024, and later fell by 6.67% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $3.0 million in 2023, then soared by 34.85% to $4.0 million in 2024, then fell by 2.07% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.4 million for Q2 2025, and $2.8 million during Q1 2025.